MBP-1 Upregulates MiR-29b That Represses Mcl-1, Collagens, and Matrix-metalloproteinase-2 in Prostate Cancer Cells

Overview

Journal Genes Cancer

Specialty Oncology

Date 2010 Jul 27

PMID 20657750

Citations 74

Authors

Robert Steele

Justin L Mott

Ratna B Ray

Affiliations

Soon will be listed here.

Abstract

c-myc promoter binding protein (MBP-1) is a multi-functional protein known to regulate expression of targets involved in the malignant phenotype. We have previously demonstrated that exogenous expression of MBP-1 inhibits prostate tumor growth, although the mechanism of growth inhibition is not well understood. We hypothesized that MBP-1 may modulate microRNA (miRNA) expression for regulation of prostate cancer cell growth. In this study, we demonstrated that exogenous MBP-1 upregulates miR-29b by 5-9 fold in prostate cancer cells as measured by real-time quantitative reverse transcription-PCR. Subsequent studies indicated that exogenous expression of miR-29b inhibited Mcl-1, COL1A1, and COL4A1. Further, a novel target with potential implications for invasion and metastasis, matrix metallopeptidase-2 (MMP-2), was identified and confirmed to be a miR-29b target in prostate cancer cells. Together our results demonstrated that exogenous expression of miR-29b regulates prostate cancer cell growth by modulating anti-apoptotic and pro-metastatic matrix molecules, implicating therapeutic potential of miR-29b for prostate cancer inhibition.

Citing Articles

Integrative analyses of mendelian randomization and bioinformatics reveal casual relationship and genetic links between COVID-19 and knee osteoarthritis.

Zheng X, Li J, Ma Q, Gong J, Pan J BMC Med Genomics. 2025; 18(1):2.

PMID: 39748395 PMC: 11697936. DOI: 10.1186/s12920-024-02074-4.

Therapeutic and Diagnostic Potential of Folic Acid Receptors and Glycosylphosphatidylinositol (GPI) Transamidase in Prostate Cancer.

Hoffmann M, Ermler T, Hoffmann F, Alexa R, Kranz J, Steinke N Cancers (Basel). 2024; 16(11).

PMID: 38893127 PMC: 11170984. DOI: 10.3390/cancers16112008.

From biology to the clinic - exploring liver metastasis in prostate cancer.

Ni X, Wei Y, Li X, Pan J, Fang B, Zhang T Nat Rev Urol. 2024; 21(10):593-614.

PMID: 38671281 DOI: 10.1038/s41585-024-00875-x.

Hypoxic Effects on Matrix Metalloproteinases' Expression in the Tumor Microenvironment and Therapeutic Perspectives.

Gonzalez-Avila G, Sommer B, Flores-Soto E, Aquino-Galvez A Int J Mol Sci. 2023; 24(23).

PMID: 38069210 PMC: 10707261. DOI: 10.3390/ijms242316887.

HIF‑1α and MBP1 are associated with the progression of breast cancer cells by repressing β‑catenin transcription.

Zhuang Y, Li X, Zhan P, Pi G, Wen G Oncol Rep. 2022; 48(3).

PMID: 35796020 PMC: 9350992. DOI: 10.3892/or.2022.8361.

References

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

Ray R, Miller D . Cloning and characterization of a human c-myc promoter-binding protein. Mol Cell Biol. 1991; 11(4):2154-61. PMC: 359903. DOI: 10.1128/mcb.11.4.2154-2161.1991. View

Hurst D, Edmonds M, Welch D . Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009; 69(19):7495-8. PMC: 2756311. DOI: 10.1158/0008-5472.CAN-09-2111. View

Michels J, Johnson P, Packham G . Mcl-1. Int J Biochem Cell Biol. 2004; 37(2):267-71. DOI: 10.1016/j.biocel.2004.04.007. View

Ramaswamy S, Ross K, Lander E, Golub T . A molecular signature of metastasis in primary solid tumors. Nat Genet. 2002; 33(1):49-54. DOI: 10.1038/ng1060. View

Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J . Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis. 2004; 7(4):327-32. DOI: 10.1038/sj.pcan.4500750. View

Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S . Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res. 2004; 33(1):44-50. DOI: 10.1007/s00240-004-0440-8. View

Theret N, Musso O, Turlin B, Lotrian D, Bioulac-Sage P, Campion J . Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology. 2001; 34(1):82-8. DOI: 10.1053/jhep.2001.25758. View

Shintani Y, Hollingsworth M, Wheelock M, Johnson K . Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 2006; 66(24):11745-53. DOI: 10.1158/0008-5472.CAN-06-2322. View

10.

Koenig A, Mueller C, Hasel C, Adler G, Menke A . Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006; 66(9):4662-71. DOI: 10.1158/0008-5472.CAN-05-2804. View

11.

Petrylak D, Tangen C, Hussain M, Lara Jr P, Jones J, Taplin M . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15):1513-20. DOI: 10.1056/NEJMoa041318. View

12.

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

13.

So A, Gleave M, Hurtado-Col A, Nelson C . Mechanisms of the development of androgen independence in prostate cancer. World J Urol. 2005; 23(1):1-9. DOI: 10.1007/s00345-004-0473-1. View

14.

Pfohler C, Fixemer T, Jung V, Dooley S, Remberger K, Bonkhoff H . In situ hybridization analysis of genes coding collagen IV alpha1 chain, laminin beta1 chain, and S-laminin in prostate tissue and prostate cancer: increased basement membrane gene expression in high-grade and metastatic lesions. Prostate. 1998; 36(3):143-50. DOI: 10.1002/(sici)1097-0045(19980801)36:3<143::aid-pros1>3.0.co;2-i. View

15.

Chang T, Yu D, Lee Y, Wentzel E, Arking D, West K . Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2007; 40(1):43-50. PMC: 2628762. DOI: 10.1038/ng.2007.30. View

16.

Mott J, Kobayashi S, Bronk S, Gores G . mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007; 26(42):6133-40. PMC: 2432524. DOI: 10.1038/sj.onc.1210436. View

17.

Krajewska M, Krajewski S, Epstein J, Shabaik A, Sauvageot J, Song K . Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996; 148(5):1567-76. PMC: 1861561. View

18.

Li Z, Hassan M, Jafferji M, Aqeilan R, Garzon R, Croce C . Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem. 2009; 284(23):15676-84. PMC: 2708864. DOI: 10.1074/jbc.M809787200. View

19.

Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K . Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995; 146(6):1309-19. PMC: 1870904. View

20.

Sengupta S, den Boon J, Chen I, Newton M, Stanhope S, Cheng Y . MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A. 2008; 105(15):5874-8. PMC: 2311339. DOI: 10.1073/pnas.0801130105. View